P14.19 CD8α-Enhanced NY-ESO-1-Specific TCR T Cells (GSK3901961) in HLA-A*02 Patients with NSCLC: Master Protocol Substudy 1

Letetresgene autoleucel (lete-cel; GSK3377794) is an autologous T cell therapy engineered to express a modified T cell receptor (TCR) to improve recognition of NY-ESO-1 and/or LAGE-1a expressing cancer cells. Early clinical studies in a broad range of solid tumors have shown encouraging clinical activity [1-4]; lete-cel is currently being evaluated in NSCLC [3], where NY-ESO-1 and LAGE-1a expression occur in 20–30% and 16% of tumors, respectively [5-6]. To improve the therapeutic potential of lete-cel, additional genetic modifications are being incorporated into next generation cell therapies that could further enhance anticancer activity.